» Articles » PMID: 12960092

Overexpressed Pituitary Tumor-transforming Gene Causes Aneuploidy in Live Human Cells

Overview
Journal Endocrinology
Specialty Endocrinology
Date 2003 Sep 10
PMID 12960092
Citations 42
Authors
Affiliations
Soon will be listed here.
Abstract

The mammalian securin, pituitary tumor-transforming gene (PTTG), is overexpressed in several tumors and transforms cells in vitro and in vivo. To test the hypothesis that PTTG overexpression causes aneuploidy, enhanced green fluorescent protein (EGFP)-tagged PTTG (PTTG-EGFP) was expressed in human H1299 cancer cells (with undetectable endogenous PTTG expression) and mitosis of individual live cells observed. Untransfected cells and cells expressing EGFP alone exhibited appropriate mitosis. PTTG-EGFP markedly prolonged prophase and metaphase, indicating that PTTG blocks progression of mitosis to anaphase. In cells that underwent apparently normal mitosis (35 of 65 cells), PTTG-EGFP was degraded about 1 min before anaphase onset. Cells that failed to degrade PTTG-EGFP exhibited asymmetrical cytokinesis without chromosome segregation (18 of 65 cells) or chromosome decondensation without cytokinesis (9 of 65 cells), resulting in appearance of a macronucleus. Fifty-one of 55 cells expressing a nondegradable mutant PTTG exhibited asymmetrical cytokinesis without chromosome segregation, and some (4 of 55) decondensed chromosomes, both resulting in macronuclear formation. During this abnormal cytokinesis, all chromosomes and spindles and both centrosomes moved to one daughter cell, suggesting potential chaos in the subsequent mitosis. In conclusion, failure of PTTG degradation or enhanced PTTG accumulation, as a consequence of overexpression, inhibits mitosis progression and chromosome segregation but does not directly affect cytokinesis, resulting in aneuploidy. These results demonstrate that PTTG induces aneuploidy in single, live, human cancer cells.

Citing Articles

Smarca4 deficiency induces Pttg1 oncogene upregulation and hyperproliferation of tubular and interstitial cells during kidney development.

Xu J, Zhou X, Zhang T, Zhang B, Xu P Front Cell Dev Biol. 2023; 11:1233317.

PMID: 37727504 PMC: 10506413. DOI: 10.3389/fcell.2023.1233317.


Causes, consequences and clinical significance of aneuploidy across melanoma subtypes.

Shteinman E, Wilmott J, Pires da Silva I, Long G, Scolyer R, Vergara I Front Oncol. 2022; 12:988691.

PMID: 36276131 PMC: 9582607. DOI: 10.3389/fonc.2022.988691.


Gene signatures and prognostic analyses of the Tob/BTG pituitary tumor-transforming gene (PTTG) family in clinical breast cancer patients.

Wu C, Ekanem T, Phan N, Loan D, Hou S, Lee K Int J Med Sci. 2020; 17(18):3112-3124.

PMID: 33173433 PMC: 7646110. DOI: 10.7150/ijms.49652.


DNA damage and growth hormone hypersecretion in pituitary somatotroph adenomas.

Ben-Shlomo A, Deng N, Ding E, Yamamoto M, Mamelak A, Chesnokova V J Clin Invest. 2020; 130(11):5738-5755.

PMID: 32673291 PMC: 7598090. DOI: 10.1172/JCI138540.


Therapeutic Potency of Nanoformulations of siRNAs and shRNAs in Animal Models of Cancers.

Karim M, Tha K, Othman I, Uddin M, Chowdhury E Pharmaceutics. 2018; 10(2).

PMID: 29861465 PMC: 6026921. DOI: 10.3390/pharmaceutics10020065.